Replies to post #1253 on Conatus Pharmaceuticals Inc. (CNAT)

[realfast95]

So getting back to my questions regarding safety. If you targeting the sickest patients, nothing is safe. You at a higher risk of a failed trial because they die too quick. If what your saying about GILD trials is with less sick patients, who will survive longer, and therefore be able to measure easier and for a longer duration.

CNAT is going to bat with only a home run available to win the game.
CNAT trials are P3 by default and by design. There isn't a P2 trial.